Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries

Figure 4

Cost-effectiveness of CRC screening under different scenarios. Abbreviations: CRC, colorectal cancer; DNA3, DNA5, and DNA10, stool DNA testing every 3, 5, and 10 years, respectively; -W, under the worst case scenario (the same with the base-case estimates) in which the sensitivity of stool DNA testing for small adenoma, large adenoma, and colorectal cancer, and the specificity are 8%, 15%, 52%, and 94% based on Imperiale et al study [10]; -M, under the moderate case scenario in which the corresponding estimates are 8%, 18%, 85%, and 94% based on meta-analysis [10-13, 16]; -B, under the best case scenario in which the corresponding estimates are 8%, 82%, 91%, and 93% based on Ahlquist et al study [10]; FOBT1, fecal occult blood testing every year; SIGM5, sigmoidoscopy every 5 years; COLO10, colonoscopy every 10 years.

Back to article page